XOMA Corporation acquired Rights to Ebopiprant from ObsEva SA for $113 million.
XOMA Corporation (NasdaqGM:XOMA) completed the acquisition of Rights to Ebopiprant from ObsEva SA (NasdaqGS:OBSV) on November 22, 2022.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0001 USD | 0.00% | +9,900.00% | -99.71% |
2023 | ObsEva to Suspend Reporting With SEC Following Delisting From Nasdaq | MT |
2023 | ObsEva to Change Central Securities Depositary to SIX SIS; Shares Up 9% | MT |
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
25 USD | +1.79% | -3.47% | 286M | ||
0.0001 USD | 0.00% | +9,900.00% | 11.72K | ||
1st Jan change | Capi. | |
---|---|---|
-99.71% | 11.72K | |
+20.33% | 125B | |
+21.60% | 114B | |
+25.30% | 26.73B | |
-23.38% | 19.43B | |
-18.10% | 16.22B | |
-18.62% | 15.33B | |
+11.05% | 14.42B | |
-48.41% | 14.33B | |
+54.91% | 14.2B |